All Posts
173 posts
Eli Lilly (LLY): What This Company Actually Does
A plain-English read of Eli Lilly's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-28The StoryEli Lilly's Last Three Years: A Company That Couldn't Keep Up With Its Own Success
How Mounjaro and Zepbound demand kept outrunning Eli Lilly's own guidance — and how the two moments that looked like trouble both turned into launching pads for the next raise.
2026-09-28Reverse DCFWhat LLY's Stock Price Is Really Betting On
Reverse-engineering the growth rate Eli Lilly's current share price already assumes — and why the answer swings wildly depending on which year's cash flow you use as a baseline.
2026-09-28Company SnapshotAbbVie (ABBV): What This Company Actually Does
A plain-English read of AbbVie's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-27The StoryAbbVie's Last Three Years: 'Raising Guidance' While the Number Keeps Falling
How a CEO transition and a buying spree turned AbbVie's own guidance language into a puzzle worth decoding every quarter.
2026-09-27Reverse DCFWhat ABBV's Stock Price Is Really Betting On
Reverse-engineering the growth rate AbbVie's current share price already assumes — and checking it against five years of shrinking free cash flow.
2026-09-27Company SnapshotLeidos (LDOS): What This Company Actually Does
A plain-English read of Leidos' business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-24Company SnapshotAAR Corp. (AIR): What This Company Actually Does
A plain-English read of AAR's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-24Reverse DCFWhat AIR's Stock Price Is Really Betting On
Reverse-engineering the growth rate AAR's current share price already assumes — and why a thin, volatile free-cash-flow base makes that number unusually large.
2026-09-24The StoryAAR Corp.'s Last Three Years: A $55.6 Million Settlement and a Corporate Makeover
How a foreign-bribery settlement and a criminal case against its own CEO coincided with the company cutting its slowest-growing businesses and doubling down on M&A.
2026-09-24Reverse DCFWhat MRCY's Stock Price Is Really Betting On
Reverse-engineering the growth rate Mercury Systems' current share price already assumes — and checking it against a business that's barely grown its top line.
2026-09-24Company SnapshotKratos Defense (KTOS): What This Company Actually Does
A plain-English read of Kratos's business model, built directly from its SEC filings — no hype, just where the money comes from.
2026-09-24